Researchers Are Able To Restore Brain Function in Just a Few Hours Using Models of Autistic Brains

Can the brain change in just two hours? A new study has shown that a single treatment was able to rapidly reverse brain changes and autism-like behaviors in adult mice. The discovery reveals the impressive power of neuroplasticity and may open new doors for future therapies.

Autism spectrum disorder is a neurodevelopmental condition that affects millions of people worldwide. Although symptoms usually appear in childhood, scientists know that they can arise from different combinations of genetic, environmental, and biological factors.

Among the most studied alterations is an important communication pathway between brain cells called mTOR. It functions as a kind of "control center," regulating the growth of nerve cells, the formation of connections between neurons, the balance of brain activity, and even the body's response to inflammation.

When this pathway functions excessively, it can contribute to alterations observed in some cases of autism, such as sensory hypersensitivity, repetitive behaviors, and social difficulties.

The new study investigated a question that has intrigued researchers for years: is it possible to rapidly improve the functioning of the adult brain, even when the changes arose during development?

To answer this question, scientists used a mouse model in which mild inflammation during gestation causes brain and behavioral changes similar to those observed in some people with autism. This model had already shown that the animals exhibit greater sensitivity to stimuli, repetitive behaviors, and changes in how different brain regions communicate.

In the experimental phase, the researchers administered a single dose of rapamycin, a drug known to reduce the activity of the mTOR pathway, to adult mice. Unlike previous research, which used treatments for weeks or months, this time the goal was to observe only the immediate effects of the drug. In the following two hours, the animals underwent a series of evaluations.

Their repetitive behaviors, response to sounds and sensory stimuli, tests to measure brain electrical activity, techniques to observe how different brain regions communicated, and genetic analyses to verify which genes had changed activity after treatment were analyzed.

The results surprised even the researchers themselves. Just two hours after receiving the medication, the mice showed significant improvement in several aspects. They became less sensitive to environmental stimuli, reduced repetitive behaviors, exhibited less electrical hyperactivity in the brain, and showed more organized communication between different brain regions.

Furthermore, genes related to autism, epilepsy, and the functioning of ion channels also began to show activity patterns closer to normal. Most interestingly, these changes occurred without the physical structure of the brain having time to modify itself, indicating that some symptoms may depend more on the functioning of neural circuits than on permanent alterations in brain anatomy.

These findings reinforce an increasingly important idea in neuroscience: even a brain that has developed differently remains capable of reorganizing its functioning.

This phenomenon, known as neuroplasticity, allows brain circuits to adjust their activity in response to treatments or experiences. The study suggests that the balance between neurons that stimulate and neurons that inhibit brain activity may be one of the main factors responsible for the observed symptoms and a promising target for future therapies.

Despite the enthusiasm, the authors themselves emphasize that the results were obtained only in mice and do not mean that there is a cure for autism or that autistic people should use rapamycin. The drug has important effects on the immune system, and many studies are still needed to assess its safety and efficacy in humans.

Even so, the research opens a promising path by showing that some aspects of brain function can respond much more quickly than previously thought, offering new possibilities for the development of treatments targeting the symptoms that most affect quality of life.

READ MORE:

Acute rapamycin treatment reveals distinct mechanisms of dysfunction in a maternal inflammation mouse model

JE Le Belle, M. C. Condro, C. Cepeda, KD Oikonomou, K. Tessema, L. Dudley, J. Schoenfield, R. Kawaguchi, D. Geschwind, AJ Silva, Z. Zhang, K. Shokat, NG Harris, and HI Kornblum

Nature Communications. 23 July 2026, 17, Article number: 6386 (2026) 

DOI: 10.1038/s41467-026-74958-1

Abstract: 

Maternal inflammatory response (MIR) during early mouse gestation induces a cascade of physiological and behavioral changes associated with autism spectrum disorder (ASD). We have shown that mild MIR causes chronic systemic and brain inflammation, mTOR pathway activation, mild brain overgrowth with regionally specific volumetric changes, sensory processing dysregulation, and repetitive behavior abnormalities. Prior rapamycin studies in autism models focused on chronic treatments that alter or prevent physical brain changes. Here, we focus on acute rapamycin effects to uncover novel mTOR pathway-mediated mechanisms of dysfunction. Within 2 hours, rapamycin rescues neuronal hyperexcitability, seizure susceptibility, functional network connectivity, brain community structure, repetitive behaviors, and sensory over-responsivity in adult MIR offspring. These CNS-mediated effects coincide with altered expression of genes associated with ASD, ion channels, and epilepsy. Our findings demonstrate that mTOR dysregulation drives dysfunctional brain development in MIR offspring but the adult brain remains amenable to rapid functional normalization, rescuing core and comorbid ASD-associated brain and behavior phenotypes. Restoring excitatory/inhibitory imbalance and sensory functional network modularity may be important targets for therapeutically addressing multiple ASD phenotypes.